Skip to main content Back to Top
Advertisement

3/13/2025

Morphine Sulfate Extended-Release Tablets

Products Affected - Description

    • MS Contin oral extended release tablet, Rhodes, 200 mg, bottle, 100 count, NDC 42858-0900-01
    • Morphine sulfate oral extended release tablet, Major, 15 mg, unit-dose blister pack, 100 count, NDC 00904-6557-61
    • Morphine sulfate oral extended release tablet, Major, 30 mg, unit-dose blister pack, 100 count, NDC 00904-6558-61
    • Morphine sulfate oral extended release tablet, Sun Pharma, 100 mg, bottle, 100 count, NDC 63304-0452-01
    • Morphine sulfate oral extended release tablet, Teva, 100 mg, bottle, 100 count, NDC 00228-4323-11
    • Morphine sulfate oral extended release tablet, Teva, 15 mg, bottle, 100 count, NDC 00228-4270-11
    • Morphine sulfate oral extended release tablet, Teva, 60 mg, bottle, 100 count, NDC 00228-4311-11

Reason for the Shortage

    • Major did not provide a reason for the shortage.
    • Mallinckrodt refuses to provide availability information.
    • Rhodes did not provide a reason for the shortage.
    • Sun Pharma did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.

Available Products

    • MS Contin oral extended release tablet, Rhodes, 100 mg, bottle, 100 count, NDC 42858-0799-01
    • MS Contin oral extended release tablet, Rhodes, 15 mg, bottle, 100 count, NDC 42858-0515-01
    • MS Contin oral extended release tablet, Rhodes, 30 mg, bottle, 100 count, NDC 42858-0631-01
    • MS Contin oral extended release tablet, Rhodes, 60 mg, bottle, 100 count, NDC 42858-0760-01
    • Morphine sulfate oral extended release tablet, Major, 100 mg, unit-dose blister pack, 100 count, NDC 00904-6560-61
    • Morphine sulfate oral extended release tablet, Major, 60 mg, unit-dose blister pack, 100 count, NDC 00904-6559-61
    • Morphine sulfate oral extended release tablet, Rhodes, 100 mg, bottle, 100 count, NDC 42858-0804-01
    • Morphine sulfate oral extended release tablet, Rhodes, 15 mg, bottle, 100 count, NDC 42858-0801-01
    • Morphine sulfate oral extended release tablet, Rhodes, 200 mg, bottle, 100 count, NDC 42858-0805-01
    • Morphine sulfate oral extended release tablet, Rhodes, 30 mg, bottle, 100 count, NDC 42858-0802-01
    • Morphine sulfate oral extended release tablet, Rhodes, 60 mg, bottle, 100 count, NDC 42858-0803-01
    • Morphine sulfate oral extended release tablet, Sun Pharma, 15 mg, bottle, 100 count, NDC 63304-0450-01
    • Morphine sulfate oral extended release tablet, Sun Pharma, 200 mg, bottle, 100 count, NDC 63304-0453-01
    • Morphine sulfate oral extended release tablet, Sun Pharma, 30 mg, bottle, 100 count, NDC 63304-0451-01
    • Morphine sulfate oral extended release tablet, Sun Pharma, 60 mg, bottle, 100 count, NDC 63304-0758-01
    • Morphine sulfate oral extended release tablet, Teva, 200 mg, bottle, 100 count, NDC 00228-4347-11
    • Morphine sulfate oral extended release tablet, Teva, 30 mg, bottle, 100 count, NDC 00228-4271-11

Estimated Resupply Dates

    • Major has morphine sulfate 15 mg and 30 mg extended-release tablets in 100 count unit-dose packages on back order and the company estimates a release date of early-May 2025 for the 15 mg tablets and early-April 2025 for the 30 mg tablets.
    • Rhodes has MS Contin 200 mg extended-release tablets in 100 count bottles on back order and the company cannot estimate a release date.
    • Sun Pharma has morphine sulfate 100 mg in 100 count bottles on back order and the company estimates a release date of mid-April 2025.
    • Teva has morphine sulfate 15 mg, 60 mg, and 100 mg extended-release tablets in 100 count bottles on back order and the company cannot estimate a release date.

Updated

Updated March 13, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. Created December 12, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT